|1.||Leung, Peter C K: 13 articles (03/2011 - 04/2003)|
|2.||Emons, Günter: 10 articles (01/2013 - 03/2002)|
|3.||Gründker, Carsten: 10 articles (01/2013 - 03/2002)|
|4.||Günthert, Andreas R: 7 articles (01/2010 - 03/2002)|
|5.||Choi, Kyung-Chul: 6 articles (01/2009 - 06/2004)|
|6.||Auersperg, Nelly: 5 articles (06/2007 - 06/2004)|
|7.||Eicke, Nicola: 4 articles (11/2006 - 07/2004)|
|8.||Seong, Jae Young: 3 articles (01/2014 - 07/2005)|
|9.||Wang, Huanping: 3 articles (01/2013 - 09/2009)|
|10.||Liu, Qiuhong: 3 articles (01/2013 - 09/2009)|
03/01/2010 - "These preliminary data suggest that local GnRH-II may participate in the regulation of ovarian tumor growth in post-menopausal women."
03/01/2010 - "The expression of GnRH-II was found to be 1.5 times higher in malignant ovarian tumors compared with benign ovarian tumors and the control group in post-menopausal patients (P<0.01). "
01/01/2010 - "GnRH-II antagonists seem to be suitable drugs for an efficacious and less-toxic endocrine therapy for breast cancers, including triple-negative breast cancers."
01/01/2010 - "The GnRH-II antagonist inhibited the growth of xenotransplants of human breast cancers in nude mice completely, without any apparent side effects. "
05/01/2009 - "GnRH-II has been shown to exert a strong antiproliferative action on tumors of the female reproductive system. "
|2.||Prostatic Neoplasms (Prostate Cancer)
02/01/2009 - "GnRH-II antagonists may hold promise in the treatment of prostate cancer."
09/01/2007 - "Further studies are warranted to characterise the effects of GnRH II on prostate cancer cells and investigate its potential value as a novel therapy."
05/01/2009 - "GnRH-II exerted an antiproliferative activity on prostate cancer cells. "
05/01/2009 - "We investigated the effects of GnRH-II on prostate cancer cell proliferation. "
05/01/2009 - "The data so far reported on the effects of GnRH-II on prostate cancer growth are controversial. "
11/01/2005 - "In the present study, we studied the possible implication of GnRH II in endometriosis. "
11/01/2005 - "In the light of the demonstrated antiproliferative and anti-inflammatory effects of GnRH II on endometrial stromal cells, the lower expression of GnRH II in eutopic and ectopic endometrium of women with endometriosis suggests that endogenous GnRH II-mediated cytostatic regulation may be impaired in the development of endometriosis."
11/01/2005 - "GnRH II as a possible cytostatic regulator in the development of endometriosis."
01/01/2013 - "GnRH-II significantly inhibited the cell proliferation, induced cell apoptosis and decreased the VEGF secreting of ectopic, eutopic and normal ESC in EMs in vitro, and these effects were the strongest on ectopic ESC, which suggested that GnRH-II may become a new effective treatment for endometriosis."
01/01/2013 - "To study the effect of GnRH-II on the cell proliferation, apoptosis and secreting vascular endothelial growth factor (VEGF) of ectopic, eutopic and normal endometrial stromal cells (ESC) from patients with or without endometriosis (EMs) in vitro. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
03/01/2011 - "GnRH-II is produced by ovarian cancer cells and enhances their invasiveness in vitro. "
02/01/2011 - "GnRH-II enhances ovarian cancer cell invasion in an autocrine manner. "
03/01/2010 - "We have shown increased GnRH-II expression in human ovarian cancer tissue in post-menopausal women in vivo. "
02/15/2007 - "Thus, GnRH-II antagonists seem to be suitable drugs for an efficacious and less toxic endocrine therapy for endometrial and ovarian cancers."
02/15/2007 - "GnRH-II antagonists inhibited the growth of xenotransplants of human endometrial and ovarian cancers in nude mice significantly, without any apparent side effects. "
|5.||Endometrial Neoplasms (Endometrial Cancer)
05/15/2009 - "However, more studies are necessary to elucidate the underlying molecular mechanisms and develop potential applications of GnRH-II. Therefore, we explored the mechanisms of GnRH-II-induced apoptosis and the effects of GnRH-II on GADD45alpha activation in human endometrial cancer cell lines. "
01/01/2013 - "Our findings represent a new concept regarding the mechanism of GnRH-II-induced cell motility in endometrial cancer cells and suggest the possibility of exploring GnRH-II as a potential therapeutic target for the treatment of human endometrial cancer."
01/01/2013 - "Here, we examined the effect of a GnRH-II agonist on the motility of endometrial cancer cells and its mechanism of action in endometrial cancer therapy. "
05/15/2009 - "This finding may provide a new concept relating to the mechanism of GnRH-II-induced antiproliferation and apoptosis in endometrial cancer cells, indicating the possibility of GnRH-II as a promising therapeutic intervention for human endometrial cancer."
01/01/2013 - "Our study indicates that GnRH-II agonist promoted cell motility of endometrial cancer cells through the GnRH-I receptor via the phosphorylation of ERK1/2 and JNK, and the subsequent, MAPK-dependent activation of MMP-2. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|4.||Messenger RNA (mRNA)
|5.||p38 Mitogen-Activated Protein Kinases
|6.||Protein Kinases (Protein Kinase)
|9.||Caspase 3 (Caspase-3)
|10.||Small Interfering RNA (siRNA)